Nicotine replacement therapy, bupropion and varenicline are pharmacotherapies that are effective in people who want to stop smoking, doubling quit rates
Nurses can make a significant contribution to improving public health and reducing health inequalities by helping patients to quit smoking. This article outlines the main options to support patients, including pharmacotherapy.
Citation: Cope L (2011) Use of pharmacotherapy in smoking cessation. Nursing Times [online]; 107: 44, 18-20.
Author: Louise Cope is senior lecturer, pharmacology and non-medical prescribing, Edge Hill University, Lancashire.
- This article has been double-blind peer reviewed
- Scroll down to read the article or download a print-friendly PDF including any tables and figures
Some 10 million adults smoke cigarettes in Great Britain and around half will eventually die from smoking-related causes (Action on Smoking and Health, 2011a). Smoking is the leading cause of preventable disease and premature death. It is one of the most significant factors in health inequalities and ill health, causing around 90% of deaths from lung cancer, 80% of deaths from bronchitis and emphysema, and 17% of deaths from heart disease (Action on Smoking and Health, 2011b). In addition, passive smoking kills over 12,000 people in the UK every year (Royal College of Physicians, 2005).
Smokers who quit improve their health and that of their families, as well as substantially reducing the likelihood that their children will become smokers (Department of Health, 2011a). The public health white paper Healthy Lives, Healthy People recognised the devastating impact of tobacco use on public health (DH, 2010); it set out to maximise efforts to reduce this via the Tobacco Control Plan, which outlines national ambitions to reduce smoking among adults and young people, and during pregnancy (DH, 2011a).
Although more than six out of ten smokers indicate a desire to quit, fewer than half of these will attempt to do so within a year (DH, 2011a). Most smokers make several attempts to quit before they succeed, so health professionals should maintain contact with them and offer re-treatment after relapse (DH, 2011b).
Overview of approaches
Smoking cessation interventions include brief interventions, individual behavioural counselling, group behaviour therapy, self-help materials, telephone counselling, helplines, mass-media campaigns and pharmacotherapy. Guidance on the standards for training in smoking cessation treatments defines three levels of smoking cessation advice (Health Development Agency, 2003):
- Level 1 – includes brief interventions;
- Level 2 – intensive one-to-one support and advice;
- Level 3 – group interventions.
Level 1 may be delivered by a variety of health professionals and usually involves offering advice for just 10 minutes. The content of the intervention depends on the smoker. Once commitment to quit has been assessed, the smoker may be offered simple advice and self-help material, pharmacotherapy and/or behavioural support or a referral to more intensive support, such as the NHS Stop Smoking Service.
Levels 2 and 3 involve face-to-face weekly meetings between an individual smoker or a group of smokers and a trained smoking cessation counsellor, usually continued for at least four weeks after the agreed quit date. Both of these are usually combined with pharmacotherapy.
Hard copy or electronic self-help materials may be used by individuals, groups or during a brief intervention/behavioural therapy session. They may be tailored so are useful when targeting specific groups, such as minority ethnic groups or when language may be a barrier.
Telephone counselling and quit lines can be proactive (counsellors can call a client) or reactive (a client may call a service). Psychological support such as counselling and brief interventions are valuable in strengthening motivation and offering coping strategies to avoid, escape or minimise the urge to smoke. Psychological support is often combined with pharmacotherapy and, together, they have a 49% successful quit rate; the quit rate is only 5% in those who quit with psychological support but without the use of pharmacotherapies (DH, 2011b).
Smokers should be assessed for their motivation to quit and degree of nicotine dependence. This lets health professionals estimate the severity of potential nicotine withdrawal symptoms and the amount and type of support needed. The tool most often used to assess the degree of nicotine addiction is the Fagerström Test for Nicotine Dependence (FTND) (Heatherton et al, 1991) (Box 1). The Heaviness of Smoking Index asks just the first and fourth questions of the FTND (Heatherton et al, 1989).
Biochemical markers can be used to measure smoking status; measuring carbon monoxide in expired air is the most cost-effective and least invasive method (DH, 2011b). A pre-quit test and a four-week post-quit reading should be made (NICE, 2008).
Box 1. The Fagerström Test for Nicotine Dependence
How soon after you wake up do you smoke your first cigarette?
- After 60 minutes (0)
- 31-60 minutes (1)
- 6-30 minutes (2)
- Within 5 minutes (3)
Do you find it difficult to refrain from smoking in places where it is forbidden?
- No (0)
- Yes (1)
Which cigarette would you hate most to give up?
- The first in the morning (1)
- Any other (0)
How many cigarettes per day do you smoke?
- 10 or less (0)
- 11-20 (1)
- 21-30 (2)
- 31 or more (3)
Do you smoke more frequently during the first hours after waking than during the rest of the day?
- No (0)
- Yes (1)
Do you smoke even if you are so ill that you are in bed most of the day?
- No (0)
- Yes (1)
0-2 = very low dependence, 3-4 = low dependence, 5 = medium dependence, 6-7 = high dependence, 8-10 = very high dependence
Source: Heatherton et al (1991)
Pharmacotherapies to support smoking cessation include nicotine replacement therapy (NRT), bupropion (Zyban) and varenicline (Champix). NRT is available as a patch (24-hour and 16-hour), gum, lozenge, sublingual tablet, nasal spray, oral spray and inhalator. It can be used instead of cigarettes after stopping smoking suddenly or to reduce the number of cigarettes smoked before a quit attempt (Royal Pharmaceutical Society and British Medical Association, 2011). No NRT product is significantly more effective than any other, but research has suggested abstinence is higher with tablets or lozenges than gum, and that nicotine nasal spray is slightly more effective than gum (DH, 2011b).
Before recommending treatment, health professionals should consider:
- Which treatments a smoker may prefer;
- Whether the smoker has tried to quit before;
- Which products, if any, the smoker has tried previously;
- Whether there are any medical reasons why a particular pharmacotherapy should not be prescribed (NICE, 2008).
Smokers with a high level of nicotine dependence or who have failed previously with NRT may benefit from a combination of an immediate-release NRT product and nicotine patches (RPS and BMA, 2011).
Most warnings for NRT also apply to continued smoking but the risks of smoking outweigh those associated with NRT (RPS and BMA, 2011).
NRT should be used with caution in patients who are haemodynamically unstable and hospitalised with severe cardiac arrhythmias, myocardial infarction or cerebrovascular accident, and in those with phaeochromocytoma or uncontrolled hyperthyroidism (RPS and BMA, 2011). Care should also be taken in patients with diabetes (blood–glucose concentrations should be monitored closely when starting NRT) and in those with moderate to severe hepatic impairment or severe renal impairment (RPS and BMA, 2011).
Smoking cessation in pregnancy should initially be tried without NRT, using non-pharmacological methods; if this fails, NRT should be considered, as using NRT in pregnancy is preferable to continued smoking (RPS and BMA, 2011). Products providing intermittent NRT are preferable to nicotine patches; liquorice-flavoured products should be avoided. In women with pregnancy-related nausea and vomiting, patches may be the better option.
While nicotine is present in breastmilk, the amount to which the baby is exposed is small and less hazardous than exposure to second-hand smoke (RPS and BMA, 2011).
Side-effects of NRT are often difficult to distinguish from nicotine withdrawal symptoms (RPS and BMA, 2011). As nicotine is an irritant, the following may occur:
- Mild skin reactions when using patches;
- Throat irritation when using oral preparations and inhalation cartridges;
- Gastrointestinal disturbances such as nausea, vomiting, dyspepsia and hiccup if nicotine is swallowed (RPS and BMA, 2011).
NRT may induce palpitations and using nicotine patches may result in abnormal dreams; this may be reduced by using a 16-hour patch or removing a patch before going to bed.
Metabolism of nicotine
Smoking stimulates a liver enzyme responsible for metabolising certain medicines. This means their metabolism is increased, resulting in lower blood levels, reduced therapeutic effects and a possible need for higher doses. Examples of these medicines include some antidepressants, antipsychotics, benzodiazepines, insulin, opiates, tamoxifen theophylline, warfarin and verapamil (RPS and BMA, 2011).
It is vital to review patients’ medication before starting cessation treatment, and to consider and plan for possible dosage reduction after quitting. Some people metabolise nicotine faster than others, so may need higher doses of NRT (DH, 2011b).
Bupropion (Zyban) raises successful quit rates (Hughes et al, 2007). Licensed for adults over 18 years, it is prescription only. Its mechanism is unclear but it is thought to affect noradrenaline and dopamine.
Bupropion has antidepressant properties but some people may experience depression as a side-effect. Its use is not recommended in combination with NRT or other smoking cessation medicines (RPS and BMA, 2011) and it should not be used during pregnancy or breastfeeding. Its dose should be reduced in renal and hepatic impairment; there are also other cautions and contraindications (RPS and BMA, 2011).
Common side-effects include dry mouth, gastrointestinal upset, agitation, dizziness, depression, headache, impaired concentration, insomnia (avoid dose at bedtime), tremor, fever, pruritis, rash and sweating (RPS and BMA, 2011).
Varenicline (Champix) blocks nicotine receptors, and so reduces withdrawal effects. It is a prescription-only medicine, licensed for adults aged over 18 years. Its use is not recommended in combination with NRT or other medicines used in smoking cessation (RPS and BMA, 2011), or during pregnancy or breastfeeding, and its dose should be reduced in renal impairment.
Varenicline increases the chances of long-term abstinence from nicotine two- to threefold and is more effective than bupropion (Cahill et al, 2011). Common side-effects include nausea (subsides over time), changes in appetite, dry mouth, taste disturbance, headache, drowsiness, dizziness, sleep disorders and abnormal dreams (RPS and BMA, 2011).
Suicide-related events have been reported by the Medicines and Healthcare products Regulatory Agency (2010) in people with no psychiatric history. Patients should be advised to stop treatment and seek prompt medical advice if they develop agitation, depressed mood or suicidal thoughts. People with a history of psychiatric illness should be monitored closely (RPS and BMA, 2011; MHRA, 2010).
Cessation pharmacotherapies – NRT, bupropion and varenicline – are effective in people who want to stop smoking. On average, successful quit rates are doubled by using these products (Cahill et al, 2011; Hughes et al, 2007; NPC, 1999). These rates improve significantly further when combined with level 2 or level 3 smoking cessation support. Nurses should encourage people to attend a level 2 or 3 service.
- Smoking is the leading cause of preventable disease and premature death
- Most smokers make several attempts to quit before succeeding
- Many smoking cessation interventions are effective
- Patients should be assessed for intention and motivation to quit, and degree of nicotine dependence
- Side-effects of nicotine replacement therapy are often difficult to distinguish from nicotine withdrawal symptoms
Action on Smoking and Health (2011a) Facts at a Glance: Smoking Statistics.
Action on Smoking and Health (2011b) Facts at a Glance: Smoking and Disease.
Cahill K et al (2011) Nicotine receptor or partial agonists for smoking cessation. Cochrane Database of Systematic Reviews; 2011: 2, CD006103.
Department of Health (2011a) Healthy Lives, Healthy People: A Tobacco Control Plan for England. London: DH.
Department of Health (2011b) Local Stop Smoking Services – Service Delivery and Monitoring Guidance 2011/12. London: DH.
Department of Health (2010) Healthy Lives, Healthy People: Our Strategy for Public Health in England. London: TSO.
Health Development Agency (2003) Standard for Training in Smoking Cessation Treatments.
Heatherton TF et al (1991) The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction; 86: 9, 1119-1127.
Heatherton TF et al (1989) Measuring the heaviness of smoking: using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. Addiction; 84: 791-800.
Hughes J et al (2007) Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews; 2007; 1: CD000031.
Medicines and Healthcare products Regulatory Agency (2010) Varenicline: Adverse Psychiatric Reactions, Including Depression.
National Institute for Health and Clinical Excellence (2008) Smoking Cessation Services in Primary Care, Pharmacies, Local Authorities and Workplaces, Particularly for Manual Working Groups, Pregnant Women and Hard to Reach Communities. London: NICE.
National Prescribing Centre (1999) Nicotine replacement therapy. MeReC Bulletin; 10: 3, 9-12.
Royal College of Physicians (2005) Going Smoke-Free. The Medical Case for Clean Air in the Home, at Work and in Public Places. A Report on Passive Smoking by the Tobacco Advisory Group of the RCP. London: RCP.
Royal Pharmaceutical Society and British Medical Association (2011) British National Formulary. London: BMJ Group and Pharmaceutical Press.